ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO

被引：0

作者：

Liang, Muh-Lii ^{[1
]}

Hsieh, Tsung-Han ^{[2
]}

Wong, Tai-Tong ^{[3
]}

机构：

[1] Mackay Mem Hosp, Dept Neurosurg, Taipei, Taiwan

[2] Taipei Med Univ, Off Human Res, Joint Biobank, Taipei, Taiwan

[3] Taipei Med Univ Hosp, Dept Neurosurg, Taipei, Taiwan

来源：

NEURO-ONCOLOGY | 2020年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MODL-16

引用

页码：414 / 414

页数：1

共 50 条

[31] Characterization of a novel potent and selective CDK4/6 inhibitor and a resistance mechanism
Dai, Kang
Li, Cong
Liang, Lingming
Rong, Minging
Orf, Jessica
Keegan, Kathy
Li, Zhihong
Fu, Jiasheng
Ma, Ji
Carlson, Tim
McGee, Larry
Medina, Julio
Kamb, Alexander
Wickramasinghe, Dineli
CANCER RESEARCH, 2012, 72
[32] Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo
Elango, Ramesh
Vishnubalaji, Radhakrishnan
Manikandan, Muthurangan
Binhamdan, Sarah Ibrahim
Siyai, Abdul-Aziz
Alshawakir, Yasser A.
Alfayez, Musaad
Aldahmash, Abdullah
Alajez, Nehad M.
SCIENTIFIC REPORTS, 2019, 9 (1)
[33] Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo
Ramesh Elango
Radhakrishnan Vishnubalaji
Muthurangan Manikandan
Sarah Ibrahim Binhamdan
Abdul-Aziz Siyal
Yasser A. Alshawakir
Musaad Alfayez
Abdullah Aldahmash
Nehad M. Alajez
Scientific Reports, 9
[34] CDK4/6 inhibitor abemaciclib has been established in early as well as locally advanced and metastatic settings
不详
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (04) : 156 - 157
[35] Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
Sun, Chao-Yue
Talukder, Milton
Cao, Di
Chen, Cun-Wu
FRONTIERS IN PHARMACOLOGY, 2022, 13
[36] Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Morschhauser, Franck
Bouabdallah, Kamal
Stilgenbauer, Stephan
Thieblemont, Catherine
Wolf, Martin
de Guibert, Sophie
Zettl, Florian
Hahka-Kemppinen, Marjo
Wang, David Xiaohui
Brueck, Patrick
Caldwell, Charles
Beckmann, Richard
Gelbert, Lawrence
Cronier, Damien
Lin, Ji
Li, Lily
Chan, Edward M.
Pfreundschuh, Michael
Wilhem, Martin
Hess, Georg
BLOOD, 2014, 124 (21)
[37] Preclinical selectivity profile of the CDK4/6 inhibitor ribociclib (LEE011) compared with that of palbociclib and abemaciclib
Tiedt, Ralph
Delach, Scott
Kovats, Steven
Horn, Thomas
Acker, Michael
Engstler, Barbara Schacher
Caponigro, Giordano
Su, Fei
CANCER RESEARCH, 2017, 77
[38] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
Corona, Silvia Paola
Generali, Daniele
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
[39] Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
Zhang, Yi-Xiang
Sicinska, Ewa
Czaplinski, Jeffrey T.
Remillard, Stephen P.
Moss, Samuel
Wang, Yuchuan
Brain, Christopher
Loo, Alice
Snyder, Eric L.
Demetri, George D.
Kim, Sunkyu
Kung, Andrew L.
Wagner, Andrew J.
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (09) : 2184 - 2193
[40] Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Gong, Xueqian
Litchfield, Lacey M.
Webster, Yue
Chio, Li-Chun
Wong, Swee Seong
Stewart, Trent R.
Dowless, Michele
Dempsey, Jack
Zeng, Yi
Torres, Raquel
Boehnke, Karsten
Mur, Cecilia
Marugan, Carlos
Baquero, Carmen
Yu, Chunping
Bray, Steven M.
Wulur, Isabella H.
Bi, Chen
Chu, Shaoyou
Qian, Hui-Rong
Iversen, Philip W.
Merzoug, Farhana F.
Ye, Xiang S.
Reinhard, Christoph
De Dios, Alfonso
Du, Jian
Caldwell, Charles W.
Jose Lallena, Maria
Beckmann, Richard P.
Buchanan, Sean G.
CANCER CELL, 2017, 32 (06) : 761 - +

← 1 2 3 4 5 →